S&P 500   4,282.37
DOW   33,762.76
QQQ   354.06
Will Nvidia Be the Lifeline Intel Desperately Needs?
New "Mined in America" Lithium Opportunities? (Ad)
Stock market today: Crude prices are up after Saudi cuts, but energy prices way down from last year
Is Li Auto Head and Shoulders Above Its Chinese Counterparts?
AI industry Is Exploding! New Breakthrough Expected this Summer (Ad)
Analysts are Giving ChargePoint a Boost, but is it a Buy?
VirTra is an Overlooked Profitable National Defense Play
AI industry Is Exploding! New Breakthrough Expected this Summer (Ad)
Here’s Why Disney’s MCU is Sinking in Quicksand
Risk-On In Small-Caps After iShares Russell 2000 ETF Breaks Out
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.06
Will Nvidia Be the Lifeline Intel Desperately Needs?
New "Mined in America" Lithium Opportunities? (Ad)
Stock market today: Crude prices are up after Saudi cuts, but energy prices way down from last year
Is Li Auto Head and Shoulders Above Its Chinese Counterparts?
AI industry Is Exploding! New Breakthrough Expected this Summer (Ad)
Analysts are Giving ChargePoint a Boost, but is it a Buy?
VirTra is an Overlooked Profitable National Defense Play
AI industry Is Exploding! New Breakthrough Expected this Summer (Ad)
Here’s Why Disney’s MCU is Sinking in Quicksand
Risk-On In Small-Caps After iShares Russell 2000 ETF Breaks Out
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.06
Will Nvidia Be the Lifeline Intel Desperately Needs?
New "Mined in America" Lithium Opportunities? (Ad)
Stock market today: Crude prices are up after Saudi cuts, but energy prices way down from last year
Is Li Auto Head and Shoulders Above Its Chinese Counterparts?
AI industry Is Exploding! New Breakthrough Expected this Summer (Ad)
Analysts are Giving ChargePoint a Boost, but is it a Buy?
VirTra is an Overlooked Profitable National Defense Play
AI industry Is Exploding! New Breakthrough Expected this Summer (Ad)
Here’s Why Disney’s MCU is Sinking in Quicksand
Risk-On In Small-Caps After iShares Russell 2000 ETF Breaks Out
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.06
Will Nvidia Be the Lifeline Intel Desperately Needs?
New "Mined in America" Lithium Opportunities? (Ad)
Stock market today: Crude prices are up after Saudi cuts, but energy prices way down from last year
Is Li Auto Head and Shoulders Above Its Chinese Counterparts?
AI industry Is Exploding! New Breakthrough Expected this Summer (Ad)
Analysts are Giving ChargePoint a Boost, but is it a Buy?
VirTra is an Overlooked Profitable National Defense Play
AI industry Is Exploding! New Breakthrough Expected this Summer (Ad)
Here’s Why Disney’s MCU is Sinking in Quicksand
Risk-On In Small-Caps After iShares Russell 2000 ETF Breaks Out
NASDAQ:ONCT

Oncternal Therapeutics (ONCT) Competitors

$0.30
0.00 (-0.65%)
(As of 08:34 AM ET)
Compare
Today's Range
$0.30
$0.30
50-Day Range
$0.28
$0.82
52-Week Range
$0.26
$1.57
Volume
300 shs
Average Volume
410,602 shs
Market Capitalization
$17.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.77

ONCT vs. CMMB, BNOX, NHWK, HGEN, TNXP, ATHX, TFFP, NRSN, LSDI, and ZYNE

Should you be buying Oncternal Therapeutics stock or one of its competitors? The main competitors of Oncternal Therapeutics include Chemomab Therapeutics (CMMB), Bionomics (BNOX), NightHawk Biosciences (NHWK), Humanigen (HGEN), Tonix Pharmaceuticals (TNXP), Athersys (ATHX), TFF Pharmaceuticals (TFFP), NeuroSense Therapeutics (NRSN), Lucy Scientific Discovery (LSDI), and Zynerba Pharmaceuticals (ZYNE). These companies are all part of the "pharmaceutical preparations" industry.

Oncternal Therapeutics vs.

Oncternal Therapeutics (NASDAQ:ONCT) and Chemomab Therapeutics (NASDAQ:CMMB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, community ranking, earnings and risk.

Oncternal Therapeutics has a beta of 1.54, suggesting that its stock price is 54% more volatile than the S&P 500. Comparatively, Chemomab Therapeutics has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500.

Chemomab Therapeutics has lower revenue, but higher earnings than Oncternal Therapeutics. Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Oncternal Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oncternal Therapeutics$1.49 million11.98-$44.17 million-$0.84-0.36
Chemomab TherapeuticsN/AN/A-$27.65 million-$2.76-0.64

In the previous week, Oncternal Therapeutics had 1 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 2 mentions for Oncternal Therapeutics and 1 mentions for Chemomab Therapeutics. Oncternal Therapeutics' average media sentiment score of 0.62 beat Chemomab Therapeutics' score of 0.33 indicating that Oncternal Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oncternal Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Chemomab Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Oncternal Therapeutics received 13 more outperform votes than Chemomab Therapeutics when rated by MarketBeat users. However, 52.63% of users gave Chemomab Therapeutics an outperform vote while only 46.94% of users gave Oncternal Therapeutics an outperform vote.

CompanyUnderperformOutperform
Oncternal TherapeuticsOutperform Votes
23
46.94%
Underperform Votes
26
53.06%
Chemomab TherapeuticsOutperform Votes
10
52.63%
Underperform Votes
9
47.37%

16.7% of Oncternal Therapeutics shares are owned by institutional investors. Comparatively, 34.8% of Chemomab Therapeutics shares are owned by institutional investors. 8.0% of Oncternal Therapeutics shares are owned by insiders. Comparatively, 11.9% of Chemomab Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Chemomab Therapeutics has a net margin of 0.00% compared to Oncternal Therapeutics' net margin of -4,831.36%. Oncternal Therapeutics' return on equity of -71.49% beat Chemomab Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Oncternal Therapeutics -4,831.36% -71.49% -64.30%
Chemomab Therapeutics N/A -77.93% -67.79%

Oncternal Therapeutics currently has a consensus target price of $5.77, indicating a potential upside of 1,784.53%. Chemomab Therapeutics has a consensus target price of $7.00, indicating a potential upside of 304.62%. Given Oncternal Therapeutics' higher possible upside, analysts plainly believe Oncternal Therapeutics is more favorable than Chemomab Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oncternal Therapeutics
0 Sell rating(s)
6 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Chemomab Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Summary

Oncternal Therapeutics beats Chemomab Therapeutics on 10 of the 15 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ONCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ONCT vs. The Competition

MetricOncternal TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$17.85M$5.70B$4.45B$6.27B
Dividend YieldN/A2.61%5.95%6.50%
P/E Ratio-0.363.9281.2411.05
Price / Sales11.98321.643,483.0086.19
Price / CashN/A20.1522.0023.57
Price / Book0.284.774.635.44
Net Income-$44.17M$186.08M$115.49M$192.15M
7 Day Performance1.10%5.55%120.56%8.41%
1 Month Performance-7.88%3.07%122.40%10.24%
1 Year Performance-80.00%15.64%134.37%1.02%

Oncternal Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CMMB
Chemomab Therapeutics
1.6872 of 5 stars
$1.58
-2.5%
$7.00
+343.0%
-49.0%$17.46MN/A-0.5720
BNOX
Bionomics
1.7266 of 5 stars
$2.18
-5.6%
$10.33
+374.0%
-71.4%$17.79M$260,000.000.00N/A
NHWK
NightHawk Biosciences
0 of 5 stars
$0.68
+1.5%
N/A-72.7%$17.79M$6.38M-0.3739Gap Down
HGEN
Humanigen
1.5386 of 5 stars
$0.15
flat
$0.50
+233.3%
-93.9%$17.83M$1.70M-0.1011Upcoming Earnings
TNXP
Tonix Pharmaceuticals
1.8701 of 5 stars
$1.63
-2.4%
$40.63
+2,392.3%
-87.8%$16.85MN/A-0.0973Gap Up
ATHX
Athersys
1.6686 of 5 stars
$0.99
flat
$5.50
+455.6%
-84.0%$18.27M$5.32M-0.21104
TFFP
TFF Pharmaceuticals
2.2877 of 5 stars
$0.48
-4.0%
$5.50
+1,036.8%
-91.7%$16.84M$500,000.000.004Positive News
NRSN
NeuroSense Therapeutics
0 of 5 stars
$1.53
-4.4%
N/A+30.6%$16.74MN/A-1.423
LSDI
Lucy Scientific Discovery
0 of 5 stars
$1.13
flat
N/AN/A$18.46MN/A0.00N/ANegative News
Gap Down
ZYNE
Zynerba Pharmaceuticals
2.0509 of 5 stars
$0.31
-6.1%
$11.00
+3,448.4%
-62.8%$16.63MN/A-0.3728Gap Up
High Trading Volume

Related Companies and Tools

This page (NASDAQ:ONCT) was last updated on 6/5/2023 by MarketBeat.com Staff

My Account -